Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Extra Space Storage, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while Extra Space Storage, Inc. trades at $144.06 (market cap $31.21B). The key difference: Extra Space Storage, Inc. is far larger — about 7× ACADIA Pharmaceuticals Inc.'s market cap, and Extra Space Storage, Inc. pays a 4.39% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | EXR | |
|---|---|---|
Market Cap | $4.49B | $31.21B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $152.75 |
52-Week Low | $20.06 | $126.67 |
Enterprise Value | $3.69B | $45.01B |
Dividend Yield | — | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
EXR trades at $147.73, down 1.04% on the day, with a neutral technical signal and strong fundamentals including a 27.66% net income margin and consistent earnings beats. The company maintains robust cash flow from operations at $1.85B in 2025 and recently priced $550 million in senior notes. Analyst consensus is mixed with a $152.86 price target, while technical support sits at $144.
Outlook remains stable with revenue growth and dividend reliability, but risks include high leverage with a 46.63% debt-to-asset ratio and competitive pressures. The stock offers value near consensus targets, though margin compression and interest rate sensitivity warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
